Izon Science: Difference between revisions
| Line 19: | Line 19: | ||
}} |
}} |
||
Izon Science Ltd. provides solutions for the isolation and measurement of biological and synthetic nano-sized particles such as extracellular vesicles, lipid nanoparticles, viruses and virus-like particles, and various synthetic particles being developed for drug delivery. Their main instruments are based on principles of size exclusion chromatography and tunable resistive pulse sensing, together which are used in thousands of research institutes and universities around the world. Izon’s size-exclusion chromatography columns and related solutions are also used by diagnostics companies |
Izon Science Ltd. provides solutions for the isolation and measurement of biological and synthetic nano-sized particles such as extracellular vesicles, lipid nanoparticles, viruses and virus-like particles, and various synthetic particles being developed for drug delivery. Their main instruments are based on principles of size exclusion chromatography and tunable resistive pulse sensing, together which are used in thousands of research institutes and universities around the world. Izon’s size-exclusion chromatography columns and related solutions are also used by diagnostics companies focused on developing extracellular vesicle biomarkers. |
||
Izon Science’s headquarters are located in Addington, Christchurch, New Zealand, and the company has a wide distribution network, facilitated by collaborations with distributors, and by sales and technical support offices in Medford, Massachusetts (United States), Portland, Oregon (United States), Lyon (France) and Brisbane (Australia). All instruments are manufactured in Christchurch, New Zealand. |
Izon Science’s headquarters are located in [[Addington, Christchurch]], New Zealand, and the company has a wide global distribution network, facilitated by collaborations with distributors, and by sales and technical support offices in Medford, Massachusetts (United States), Portland, Oregon (United States), Lyon (France) and Brisbane (Australia). All instruments are manufactured in Christchurch, New Zealand. |
||
== Background/History == |
|||
The company was initially incorporated as Australo Ltd. on January 10, 2005 by four New Zealand-based scientists. In 2007, Hans van der Voorn became CEO, and the company was renamed as Izon Science Ltd. on November 18, 2008. Izon Science became focused on developing [[tunable resistive pulse sensing]] instruments for nanoparticle characterisation, and later branched into developing tools for isolating exosomes and other extracellular vesicles from biological fluids. Now, the company develops and manufactures tools for nanoparticle characterisation and separation for academic researchers and diagnostics companies working with extracellular vesicles, as well those working with nanomedicine, viruses, and virus-like particles. The Exoid is Izon’s most recent tunable resistive pulse sensing instrument, which supersedes the qViro-X, qMicro and qNano. In June 2021, Izon Science moved their headquarters from Burnside (Christchurch) to a larger 3-storey facility on Show Place, Addington (Christchurch). Izon Science is a growing company and employs approximately 70 employees. On April 1 2022, Hans van der Voorn moved from the role of CEO to Founder Director, while former ADInstruments COO Brian Travers took on the role of CEO. |
|||
Izon has received significant investment funds from Bolton Equities, a privately funded investor group based in New Zealand. Research partnerships include the [[University Medical Center Ultrecht]] and the [[VU University Medical Center]] in the Netherlands, the [[Mayo Clinic]], the [[National Institutes of Health]], and [[Massachusetts General Hospital]]. All products by Izon Science are manufactured under the ISO standard for quality management systems, ISO 13485. |
|||
== Applications & Research Fields == |
== Applications & Research Fields == |
||
Izon’s [[size-exclusion chromatography-based]] qEV isolation platform and tunable resistive pulse sensing instruments are used widely across the field of extracellular vesicle research <ref>{{cite journal |
|||
Research fields which are currently using the qNano Gold and qViro-X platforms include extracellular vesicle research, [[drug delivery]] research, virology, [[vaccinology]], gene therapy, [[microvesicles|microvesicle analysis]], nanoscience and industrial research applications, e.g. [[Microfluidics|microfluidics research]].<ref>{{cite web|url=http://macdiarmid.ac.nz/media/stories/GWillmott.php|title=The MacDiarmid Institute, Microfluidics Devices|access-date=June 20, 2011|archive-url=https://web.archive.org/web/20110727020752/http://macdiarmid.ac.nz/media/stories/GWillmott.php|archive-date=July 27, 2011|url-status=dead}}</ref> The qViro-X and qNano Gold instruments can be used in a wide range of research environments including laboratories, clinics and in the field.<ref>{{cite web|url=http://www.izon.com/about-us/collaborations/|title=Research Collaborations, Izon Science Official Website|access-date=May 16, 2011}}</ref> |
|||
| last1 = Vanderboom | first1 = Patrick |
|||
| last2 = Dasari | first2 = Surendra |
|||
| last3 = Ruegsegger | first3 = Gregory |
|||
| last4 = Pataky | first4 = Mark |
|||
| last5 = Lucien | first5 = Fabrice |
|||
| last6 = Heppelmann | first6 = Carrie |
|||
| last7 = Lanza | first7 = Ian |
|||
| last8 = Sreekumaran| first8 = Nair |
|||
| year = 2021 |
|||
| title = A size-exclusion-based approach for purifying extracellular vesicles from human plasma |
|||
| journal = Cell Reports Methods |
|||
| volume = 1 |
|||
| issue 3 |
|||
| pages: 100055 |
|||
|doi=https://doi.org/10.1016/j.crmeth.2021.100055}}</ref> and in the development of extracellular vesicle-related biomarkers and diagnostic testshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981152/ |
|||
<ref>{{cite journal |
|||
| last1 = Lane | first1 = R |
|||
| last2 = Korbie | first2 = D |
|||
| last3 = Hill | first3 = M |
|||
| last4 = Trau | first4 = M |
|||
| year = 2018 |
|||
| title = Extracellular vesicles as circulating cancer biomarkers: opportunities and challenges |
|||
| journal = Clinical and Translational Medicine |
|||
| volume = 7 |
|||
| issue 14 |
|||
|doi=10.1186/s40169-018-0192-7}}</ref> , as well as in the study of antibody preparations |
|||
<ref>{{cite journal |
|||
| last1 = Stelzl | first1 = Andreas |
|||
| last2 = Schneid | first2 = Stefan |
|||
| last3 = Winter | first3 = Gerhard |
|||
| year = 2021 |
|||
| title = Application of Tunable Resistive Pulse Sensing for the Quantification of Submicron Particles in Pharmaceutical Monoclonal Antibody Preparations |
|||
| journal = Journal of Pharmaceutical Sciences |
|||
| volume = 110 |
|||
| issue = 11 |
|||
| pages = 3541-3545 |
|||
|doi= https://doi.org/10.1016/j.xphs.2021.07.012}}</ref> , vaccines, lipid nanoparticles, and virus-like particles. <ref>{{cite journal |
|||
| last1 = Gutiérrez-Granados | first1 = Sonia |
|||
| last2 = Cervera | first2 = Laura |
|||
| last3 = de las Mercedes Segura | first3 = María |
|||
| last4 = Wölfel | last4 = Jens |
|||
| last5 = Gòdia | last5 = Francesc |
|||
| year = 2016 |
|||
| title = Optimized production of HIV-1 virus-like particles by transient transfection in CAP-T cells |
|||
| journal = Applied Microbiology and Biotechnology |
|||
| volume = 100 |
|||
| issue = 9 |
|||
| pages = 3935-3947 |
|||
|doi= https://doi.org/10.1016/j.xphs.2021.07.012}}</ref> |
|||
== References == |
== References == |
||
Revision as of 02:13, 31 March 2022
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
 | |
| Company type | Private Limited Company |
|---|---|
| Industry | Nanotechnology |
| Founded | Christchurch, New Zealand, 2005; 16 years ago |
| Founder | Hans van der Voorn |
| Headquarters | Christchurch , New Zealand |
Area served | Worldwide |
Key people | Brian Travers, CEO |
| Products | Automatic Fraction Collector, qEV columns, the Exoid |
| Website | izon |
Izon Science Ltd. provides solutions for the isolation and measurement of biological and synthetic nano-sized particles such as extracellular vesicles, lipid nanoparticles, viruses and virus-like particles, and various synthetic particles being developed for drug delivery. Their main instruments are based on principles of size exclusion chromatography and tunable resistive pulse sensing, together which are used in thousands of research institutes and universities around the world. Izon’s size-exclusion chromatography columns and related solutions are also used by diagnostics companies focused on developing extracellular vesicle biomarkers.
Izon Science’s headquarters are located in Addington, Christchurch, New Zealand, and the company has a wide global distribution network, facilitated by collaborations with distributors, and by sales and technical support offices in Medford, Massachusetts (United States), Portland, Oregon (United States), Lyon (France) and Brisbane (Australia). All instruments are manufactured in Christchurch, New Zealand.
Background/History
The company was initially incorporated as Australo Ltd. on January 10, 2005 by four New Zealand-based scientists. In 2007, Hans van der Voorn became CEO, and the company was renamed as Izon Science Ltd. on November 18, 2008. Izon Science became focused on developing tunable resistive pulse sensing instruments for nanoparticle characterisation, and later branched into developing tools for isolating exosomes and other extracellular vesicles from biological fluids. Now, the company develops and manufactures tools for nanoparticle characterisation and separation for academic researchers and diagnostics companies working with extracellular vesicles, as well those working with nanomedicine, viruses, and virus-like particles. The Exoid is Izon’s most recent tunable resistive pulse sensing instrument, which supersedes the qViro-X, qMicro and qNano. In June 2021, Izon Science moved their headquarters from Burnside (Christchurch) to a larger 3-storey facility on Show Place, Addington (Christchurch). Izon Science is a growing company and employs approximately 70 employees. On April 1 2022, Hans van der Voorn moved from the role of CEO to Founder Director, while former ADInstruments COO Brian Travers took on the role of CEO. Izon has received significant investment funds from Bolton Equities, a privately funded investor group based in New Zealand. Research partnerships include the University Medical Center Ultrecht and the VU University Medical Center in the Netherlands, the Mayo Clinic, the National Institutes of Health, and Massachusetts General Hospital. All products by Izon Science are manufactured under the ISO standard for quality management systems, ISO 13485.
Applications & Research Fields
Izon’s size-exclusion chromatography-based qEV isolation platform and tunable resistive pulse sensing instruments are used widely across the field of extracellular vesicle research [1] and in the development of extracellular vesicle-related biomarkers and diagnostic testshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981152/ [2] , as well as in the study of antibody preparations [3] , vaccines, lipid nanoparticles, and virus-like particles. [4]
References
- ^ Vanderboom, Patrick; Dasari, Surendra; Ruegsegger, Gregory; Pataky, Mark; Lucien, Fabrice; Heppelmann, Carrie; Lanza, Ian; Sreekumaran, Nair (2021). "A size-exclusion-based approach for purifying extracellular vesicles from human plasma". Cell Reports Methods. 1. doi:https://doi.org/10.1016/j.crmeth.2021.100055.
{{cite journal}}: Check|doi=value (help); External link in|doi= - ^ Lane, R; Korbie, D; Hill, M; Trau, M (2018). "Extracellular vesicles as circulating cancer biomarkers: opportunities and challenges". Clinical and Translational Medicine. 7. doi:10.1186/s40169-018-0192-7.
{{cite journal}}: Text "issue 14" ignored (help)CS1 maint: unflagged free DOI (link) - ^ Stelzl, Andreas; Schneid, Stefan; Winter, Gerhard (2021). "Application of Tunable Resistive Pulse Sensing for the Quantification of Submicron Particles in Pharmaceutical Monoclonal Antibody Preparations". Journal of Pharmaceutical Sciences. 110 (11): 3541–3545. doi:https://doi.org/10.1016/j.xphs.2021.07.012.
{{cite journal}}: Check|doi=value (help); External link in|doi= - ^ Gutiérrez-Granados, Sonia; Cervera, Laura; de las Mercedes Segura, María; Jens; Francesc (2016). "Optimized production of HIV-1 virus-like particles by transient transfection in CAP-T cells". Applied Microbiology and Biotechnology. 100 (9): 3935–3947. doi:https://doi.org/10.1016/j.xphs.2021.07.012.
{{cite journal}}: Check|doi=value (help); External link in|doi=